Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 10/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27692064 | 0.86 | HTR2C (0.46) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| SCHEMBL4329522 | 0.80 | HTR2C (0.55) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| SCHEMBL17155164 | 0.80 | HTR2C (0.55) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| SCHEMBL17154231 | 0.77 | HTR2C (0.51) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| Hydrochloric Acid SCHEMBL9530706 | 0.76 | HTR2C (0.61) | HTR2CSIGMAR1HTR6MAPTHTR2A | |
| SCHEMBL1366798 | 0.76 | HTR2C (0.61) | HTR2CSIGMAR1HTR6MAPTHTR2A | |
| SCHEMBL4699231 | 0.76 | HTR2C (0.47) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| SCHEMBL4700976 | 0.76 | HTR2C (0.48) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| Hydrochloric Acid SCHEMBL652812 | 0.75 | HTR2C (1.00) | HTR2CSIGMAR1HTR6MAPTHTR1B | |
| SCHEMBL20200674 | 0.75 | HTR2C (0.49) | HTR2CSIGMAR1HTR6MAPTHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2005117882-A2 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | HTR2C 106/4885SIGMAR1 247/4885HTR6 164/4885 |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | HTR2C 2955/4885SIGMAR1 4814/4885HTR6 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.